BTIG Research Reaffirms "Buy" Rating for Akebia Therapeutics (NASDAQ:AKBA)
BTIG Research has reiterated a "Buy" rating for Akebia Therapeutics (NASDAQ:AKBA) with a $4.00 price target, suggesting a significant upside of 203% from its current price. This endorsement comes despite a mixed analyst picture, with the company’s recent earnings showing a miss on EPS but a beat on revenue, and comes alongside significant insider buying. Akebia Therapeutics is a biopharmaceutical company focused on therapies for kidney disease, with its lead product candidate, vadadustat, targeting anemia associated with chronic kidney disease.
Akebia executives head to New York for Apr. 14 biotech investor meetings
Akebia Therapeutics (NASDAQ: AKBA) announced that its CEO, CFO/Chief Business Officer, and CMO will hold one-on-one investor meetings at the Raymond James 2026 Biotech Innovation Symposium on April 14, 2026, in New York. They plan to discuss commercial products and recent R&D Day data on their kidney disease pipeline. No formal company presentations are scheduled, and historically, similar communication events have had limited stock price impact compared to fundamental earnings news.
Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium
Akebia Therapeutics (Nasdaq: AKBA) announced that its CEO, CFO/CBO, and CMO will participate in one-on-one investor meetings at the Raymond James 2026 Biotech Innovation Symposium on April 14 in New York. The management team will discuss their commercial products and pipeline of kidney disease programs. No company presentations are planned for the symposium.
AKBA: Phase 2 Kidney Trial Will Offset Dosing Protocol Revenue Reset
Akebia Therapeutics (AKBA) is facing a revenue reset due to a new US Renal Care dosing protocol impacting Q4 Vafseo revenue and channel inventory. While analysts have trimmed price targets, potential upside remains, especially with the company initiating a Phase 2 clinical trial for praliciguat, a treatment for a rare kidney disease, which aims to diversify its pipeline and future revenue streams. The current valuation maintains a fair value of $4.40 per share, indicating the company is undervalued despite the recent Vafseo shortfall.
Akebia (AKBA) director granted 214,400 options at $1.41, 3-year vest
Akebia Therapeutics director Philip J. Vickers was granted 214,400 stock options with an exercise price of $1.41 per share, expiring on April 1, 2036. This compensation award will vest over three years: one-third on the first anniversary of the grant date, and the remaining two-thirds in equal installments quarterly thereafter, contingent on his continued service. The grant is part of the company's 2023 Plan and Non-Employee Director Compensation Program.
Akebia (NASDAQ: AKBA) director Philip J. Vickers files initial Form 3
Akebia Therapeutics, Inc. has filed an initial insider report for director Philip J. Vickers. The Form 3 filing indicates no reported transactions, derivative positions, or holding entries for Mr. Vickers at this time. This report serves to formally identify him as a reporting person due to his role as a director.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. announced the issuance of inducement grants to 13 new employees. These grants consist of options to purchase an aggregate of 679,900 shares of common stock, with an exercise price of $1.39 per share, vesting over four years. This action is in accordance with Nasdaq Listing Rule 5635(c)(4).
Akebia Therapeutics Issues Inducement Grants With Stock Options for New Employees
Akebia Therapeutics has issued inducement grants with stock options to new employees, approved by its Compensation Committee. These grants, made under Nasdaq Listing Rule 5635(c)(4), are designed to attract and retain talent and are separate from the company's existing equity incentive plans. The stock options are subject to standard vesting schedules tied to continued employment, though further details were not disclosed.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. announced that it granted 13 newly-hired employees options to purchase 679,900 shares of its common stock on March 31, 2026. These inducement grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) and have an exercise price of $1.39 per share, matching the closing price on the grant date. The options will vest over four years, with 25% vesting on the first anniversary and the remainder quarterly thereafter, subject to continued employment.
Akebia gives 13 new hires stock options for 679,900 shares
Akebia Therapeutics (Nasdaq: AKBA) granted inducement stock options for 679,900 shares to 13 new employees on March 31, 2026. The options have an exercise price of $1.39 per share, matching the closing price on the grant date, and vest over four years with a 10-year term. This action is part of Akebia's inducement award program and complies with Nasdaq Listing Rule 5635(c)(4).
Akebia brings in ex-Shire R&D chief as it weighs rare kidney assets
Akebia Therapeutics (Nasdaq: AKBA) announced the appointment of Philip J. Vickers, Ph.D., to its Board of Directors, effective April 1, 2026. Dr. Vickers brings over three decades of biopharmaceutical leadership experience, including R&D, translational science, and corporate strategy, and previously served as Global Head of R&D at Shire. Concurrently, Steven C. Gilman, Ph.D., retired from the board, a position he held since the 2018 merger with Keryx. The new appointment is expected to bolster Akebia's approach to advancing its mid- and early-stage programs in kidney and rare diseases and evaluating business development opportunities.
AKBA: Innovative kidney disease pipeline advances with major clinical and commercial catalysts ahead
Akebia Therapeutics (AKBA) is advancing a pipeline of kidney disease treatments, including praliciguat, AKB-097, and AKB-9090, which are progressing through clinical milestones. The company's drug Vafseo is generating revenue that supports research and development. Multiple catalysts are anticipated in the upcoming year for the company's clinical and commercial progress.
Akebia Therapeutics R&D Day: Vafseo Growth Plan, Praliciguat Phase 2, New Kidney Pipeline Targets
Akebia Therapeutics outlined its commercial and pipeline strategy during its R&D Day, focusing on driving significant growth for its anemia treatment, Vafseo, aiming for it to become the standard of care for dialysis patients. The company also detailed the advancement of its kidney disease pipeline, including a Phase 2 trial for praliciguat in FSGS, upcoming Phase 2 for AKB-097 (abribafisp) in rare kidney diseases, and initial Phase 1 data expected for AKB-9090 in cardiac surgery-associated AKI. These initiatives are supported by robust preclinical data and planned clinical evidence generation, positioning Akebia for future expansion in the nephrology therapeutic area.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA) granted options to purchase 679,900 shares of its common stock to 13 newly-hired employees on March 31, 2026. These grants, made as an inducement for employment, comply with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.39 per share, vest over four years, and have a 10-year term.
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors
Akebia Therapeutics announced the appointment of Philip J. Vickers, Ph.D., a biopharmaceutical leader with over three decades of experience, to its Board of Directors, effective April 1, 2026. Dr. Vickers brings extensive expertise in drug development and R&D organization leadership, which will be valuable as Akebia advances its programs in kidney and rare diseases. Concurrently, Steven C. Gilman, Ph.D., retired from the Board after significant contributions since 2016.
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers To Its Board Of Directors
Akebia Therapeutics has announced the appointment of biopharmaceutical leader Philip Vickers to its Board of Directors. This brief article from Reuters highlights the significant addition to Akebia's leadership team.
Akebia Therapeutics (AKBA) appoints Philip Vickers to Board as Steven Gilman retires
Akebia Therapeutics announced that Steven C. Gilman, Ph.D. has retired from its Board of Directors, effective April 1, 2026. Concurrently, Philip J. Vickers, Ph.D. was appointed as a new Class I director, bringing over three decades of biopharmaceutical leadership experience. Dr. Vickers will serve on the Compensation and Research & Development Committees and will receive compensation including annual cash retainers and equity grants.
Akebia Therapeutics adds Philip Vickers to board of directors By Investing.com
Akebia Therapeutics has appointed Philip J. Vickers to its board of directors. Vickers, who is currently the CEO of Solu Therapeutics and has over 30 years of biopharmaceutical leadership experience, joins the board as the company works to advance its pipeline despite a recent 48% decline in stock shares. Concurrently, Steven C. Gilman retired from the board, and the company recently reported mixed Q4 2025 earnings with revenue exceeding expectations but EPS falling significantly short.
AKBA.O PE Ratio & Valuation, Is AKBA.O Overvalued
Akebia Therapeutics Inc (AKBA.O) is currently in the "Fair zone" with a forward PS ratio of 1.93, suggesting its price is fairly valued compared to its five-year average. According to the relative valuation method, its fair price is estimated to be between $0.71 and $1.86. The article also provides current and historical valuation metrics such as P/B ratio, FCF yield, and compares its P/S ratio to competitors.
AKBA Should I Buy
This article provides an analysis of Akebia Therapeutics Inc (AKBA.O) from Intellectia AI, summarizing Wall Street analyst ratings and price target revisions. Analysts from BTIG and Piper Sandler have downgraded their price targets for Akebia, citing factors like new US Renal Care protocols impacting Vafseo revenue and general estimate adjustments ahead of Q4 reporting. Despite the downgrades, analysts maintain "Buy" or "Overweight" ratings on the stock.
Is Akebia Therapeutics (AKBA) One of the Best Penny Stocks to Buy
Akebia Therapeutics Inc. (NASDAQ:AKBA) is highlighted as a potential penny stock to buy, with expectations for its Vafseo data catalysts in the $1 billion dialysis market and expansion into rare kidney diseases. Despite a recent price target reduction by BTIG due to lower-than-expected Q4 revenue for Vafseo, the company's broader outlook for kidney disease treatments remains intact. The article also touches upon an unrelated discussion about AI stocks with significant upside potential.
10 Best Penny Stocks That Could Triple Your Money
This article features Akebia Therapeutics Inc. (NASDAQ: AKBA) as one of the 10 best penny stocks with potential for high returns. It details Akebia's 2026 pipeline expansion plans, Vafseo's performance in the dialysis market, and upcoming R&D day for rare kidney disease assets. Despite a recent price target reduction by BTIG, the firm maintained a Buy rating, acknowledging Vafseo's long-term potential.
Nordea Investment Management Boosts Stake in Akebia Therapeutics
Nordea Investment Management AB has significantly increased its stake in Akebia Therapeutics, acquiring over 750,000 shares in Q4 2025. This move signals growing institutional confidence in Akebia, a biopharmaceutical company focused on kidney disease treatments. The investment suggests positive future prospects for the company's pipeline and stock performance.
10 Best Penny Stocks That Could Triple Your Money
This article highlights Akebia Therapeutics Inc. (NASDAQ: AKBA) as one of the top 10 penny stocks with the potential to triple investors' money. Akebia recently discussed its 2026 pipeline expansion and expectations for Vafseo data catalysts in the dialysis market, reporting $227 million in net product revenue. Despite BTIG reducing its price target due to a new dosing protocol impacting Q4 revenue, the firm maintained a Buy rating, citing the company's strong broader outlook and ongoing pipeline development for kidney diseases.
Vanguard Disaggregates Holdings; Akebia (AKBA) Beneficial Ownership Reported as 0
The Vanguard Group has filed an amended Schedule 13G/A for Akebia Therapeutics (AKBA), reporting zero beneficial ownership of common stock, representing 0% of the class. This change follows an internal realignment at Vanguard effective January 12, 2026, where certain subsidiaries now report their holdings disaggregated from The Vanguard Group, Inc. The filing, signed on March 26, 2026, clarifies that Vanguard no longer has beneficial ownership of these securities.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives Average Recommendation of "Moderate Buy" from Analysts
Akebia Therapeutics (NASDAQ:AKBA) has received an average "Moderate Buy" recommendation from seven analysts, with a consensus 12-month target price of $5.40. While the company exceeded revenue estimates at $57.62 million, it missed EPS expectations and remains unprofitable. Insider activity shows mixed signals, with the CEO purchasing shares and the CAO selling some.
Is the options market predicting a spike in Akebia Therapeutics stock?
This article explores how the options market might be signaling an upcoming surge in Akebia Therapeutics (AKBA) stock. It delves into the potential implications of increased options activity for the company's share price movement.
Is the options market predicting a spike in Akebia Therapeutics stock?
The article discusses whether the options market is signaling an upcoming increase in Akebia Therapeutics (AKBA) stock. It analyzes unusual options activity as a potential indicator of future share price movements for the biotechnology company.
AKBA SEC Filings - Akebia Therapeut 10-K, 10-Q, 8-K Forms
This page provides comprehensive access to Akebia Therapeutics' SEC filings, including annual 10-K, quarterly 10-Q, and material event 8-K reports. It details recent filings such as proposed share sales by holders, amendment of executive severance deals, and updates on product commercialization and clinical trials for Vafseo (vadadustat) and Auryxia (ferric citrate). The platform also offers AI-powered summaries to help investors quickly understand key disclosures.
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026
Akebia Therapeutics announced it will host a virtual R&D Day on April 2, 2026, to showcase its kidney disease pipeline. The event will feature scientific experts who will discuss the company's clinical-stage programs, including Praliciguat for FSGS, AKB-097 for rare kidney diseases, and AKB-9090 for acute kidney injury. Management and experts will review the unmet needs and current treatment landscapes for these conditions.
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026
Akebia Therapeutics announced it will host a virtual R&D Day on April 2, 2026, to showcase its clinical-stage kidney disease pipeline. The event will feature scientific experts who will join management to discuss programs like Praliciguat for FSGS, AKB-097 for rare kidney diseases, and AKB-9090 for acute kidney injury, along with their mechanisms of action and differentiation. A live Q&A session will follow the presentations.
Three kidney disease programs take center stage at Akebia's April 2 R&D Day
Akebia Therapeutics is set to host a virtual R&D Day on April 2, 2026, to highlight its clinical-stage kidney disease pipeline. The event will feature discussions on three key programs: praliciguat (Phase 2 FSGS), AKB-097 (Phase 2 planned H2 2026), and AKB-9090 (Phase 1 planned H1 2026). External scientific experts and company management will delve into the unmet needs in rare kidney diseases, mechanisms of action, and differentiation of these product candidates, followed by a live Q&A session.
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026
Akebia Therapeutics is set to host a virtual R&D Day on April 2, 2026, to showcase its robust pipeline of clinical-stage kidney disease programs, including Praliciguat, AKB-097, and AKB-9090. The event will feature scientific experts who will join management to discuss unmet needs, current treatments, mechanisms of action, and data supporting their product candidates. A live Q&A session will follow the presentations, with a webcast available afterward on Akebia’s investor relations website.
Is the Options Market Predicting a Spike in Akebia Therapeutics Stock?
The options market is showing high implied volatility for Akebia Therapeutics (AKBA) stock, particularly for the Apr 17, 2026 $0.50 Call, suggesting investors anticipate a significant price movement. Despite this, Akebia Therapeutics currently holds a Zacks Rank #5 (Strong Sell) due to recent downward revisions of earnings estimates by analysts. Options traders might use this high implied volatility to sell premium, betting that the stock won't move as much as expected by expiration.
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference
Akebia Therapeutics announced that CEO John P. Butler and CFO Erik Ostrowski will participate in a Fireside Chat at the Leerink Partners 2026 Global Healthcare Conference on March 9, 2026, at 8:00 AM ET. A webcast of the presentation will be accessible on Akebia's investor relations website following the event. The conference is scheduled to take place from March 8-11, 2026.
Akebia Therapeutics (NASDAQ:AKBA) CEO John Butler Purchases 69,270 Shares
Akebia Therapeutics CEO John Butler recently purchased 69,270 shares of the company's stock for $86,587.50, increasing his direct ownership to 3,367,064 shares. This insider buying occurred as the stock traded down 4.8% mid-day, after the company reported quarterly earnings that missed EPS estimates but beat revenue expectations. Analysts currently have a "Moderate Buy" consensus rating for AKBA with a $5.40 price target.
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference
Akebia Therapeutics, Inc. announced that its CEO, John P. Butler, and CFO/CBO, Erik Ostrowski, will participate in a Fireside Chat at the Leerink Partners 2026 Global Healthcare Conference. The presentation is scheduled for Monday, March 9, at 8:00 AM ET, with a webcast available later on Akebia’s investor website. Akebia Therapeutics is a biopharmaceutical company focused on improving the lives of individuals with kidney disease.
Citigroup Inc. Has $5.23 Million Position in Akebia Therapeutics, Inc. $AKBA
Citigroup Inc. significantly increased its stake in Akebia Therapeutics, Inc. by 1,324.7% in the third quarter, now holding 1,916,692 shares valued at $5.23 million. Other institutional investors also adjusted their positions, with institutional ownership reaching 33.92%. Akebia Therapeutics currently has a "Moderate Buy" consensus rating from analysts, despite an EPS miss in its latest quarterly report.
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference
Akebia Therapeutics, Inc. announced that its CEO, John P. Butler, and CFO/CBO, Erik Ostrowski, will participate in a Fireside Chat at the Leerink Partners 2026 Global Healthcare Conference. The event is scheduled for Monday, March 9, at 8:00 AM ET. A webcast of the presentation will be available on Akebia's website following the conference.
Akebia Therapeutics CEO to speak at Miami Leerink 2026 healthcare forum
Akebia Therapeutics CEO John P. Butler and CFO Erik Ostrowski will participate in a Fireside Chat at the Leerink Partners 2026 Global Healthcare Conference on March 9, 2026, at 8:00 AM ET in Miami. A webcast of their presentation will be available on the company's investors website after the conference, which runs from March 8-11, 2026. This participation continues Akebia's investor outreach efforts, following recent financial reports and pipeline updates.
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference
Akebia Therapeutics, Inc. announced that its CEO, John P. Butler, and CFO, Erik Ostrowski, will participate in a Fireside Chat at the Leerink Partners 2026 Global Healthcare Conference on March 9. A webcast of the presentation will be available on the company's website after the event. The conference is scheduled from March 8-11, 2026, in Miami.
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference
Akebia Therapeutics announced that CEO John P. Butler and CFO Erik Ostrowski will participate in a Fireside Chat at the Leerink Partners 2026 Global Healthcare Conference on March 9 as the company continues to focus on improving the lives of individuals with kidney disease. A webcast of the presentation will be available on the "Investors" section of Akebia's website following the conference.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. granted stock options to five new employees to purchase an aggregate of 46,200 shares of its common stock. These grants were made as an inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.31 per share and vest over four years, subject to continued employment.
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), QuidelOrtho (QDEL) and Akebia Therapeutics (AKBA)
Healthcare sector analysts have provided updated ratings for Crinetics Pharmaceuticals (CRNX), QuidelOrtho (QDEL), and Akebia Therapeutics (AKBA). Crinetics Pharmaceuticals received a "Strong Buy" consensus with a significant upside, while QuidelOrtho was given a "Hold" rating. Akebia Therapeutics also garnered a "Strong Buy" consensus with a substantial price target increase.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2025 Earnings Call Transcript
Akebia Therapeutics, Inc. (NASDAQ: AKBA) reported its Q4 and full-year 2025 financial results, with total revenues reaching $57.6 million in Q4 and $236.2 million for the full year, driven by the commercial launch of Vafseo and increased Auryxia sales. Despite Vafseo facing challenges in late 2025, the company anticipates significant growth in 2026, supported by expanding prescriber access, improved adherence rates with in-center dosing protocols, and upcoming clinical data presentations. Akebia also highlighted its emerging rare kidney disease pipeline, including praliciguat and AKB-097, and plans an R&D day to detail these assets.
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights
Akebia Therapeutics announced its fourth quarter and full-year 2025 financial results, reporting significant revenue growth for Vafseo® (vadadustat) and Auryxia®. The company achieved $54.3 million in Q4 net product revenues and $227.3 million for the full year 2025, a 49% increase over 2024. Akebia also provided updates on its pipeline, including ongoing enrollment for a Praliciguat Phase 2 trial and planned initiation of an AKB-097 Phase 2 rare kidney disease basket trial in late 2026.
[8-K] Akebia Therapeutics, Inc. Reports Material Event | AKBA SEC Filing - Form 8-K
Akebia Therapeutics reported strong financial results for Q4 and full-year 2025, driven by Vafseo and Auryxia sales, significantly narrowing its net loss. The company anticipates continued Vafseo revenue growth in 2026 due to expanded access and improved adherence, while Auryxia revenue is expected to decline due to generic competition. Akebia also highlighted progress in its rare kidney disease pipeline with ongoing clinical trials and new acquisitions.
Akebia Therapeutics (AKBA) Loss In Q4 2025 Tests Bullish Margin Narratives
Akebia Therapeutics (AKBA) reported revenue of US$57.6 million and a basic EPS loss of US$0.05 in Q4 2025, with trailing 12-month revenue of US$236.2 million and a basic EPS loss of US$0.02. While trailing losses have narrowed significantly from FY 2024, the company's quarterly profitability remains inconsistent, swinging between profit and loss throughout FY 2025. Bullish outlooks project substantial profit margin improvement by 2028, but current results highlight challenges like product concentration risk and expected share dilution.
Akebia Therapeutics, Inc. posts full year 2025 financial results amid commercial and pipeline expansion
Akebia Therapeutics, Inc. has announced its fourth quarter and full year 2025 financial results, highlighting significant progress in its commercial operations and R&D pipeline. The company reported new momentum, including successful strategic product launches and advancements in its clinical programs. Stakeholders are monitoring Akebia's performance closely as it continues to expand within the pharmaceutical market and its key therapeutic areas.
Akebia Therapeutics (NASDAQ:AKBA) Releases Earnings Results, Misses Expectations By $0.02 EPS
Akebia Therapeutics (NASDAQ:AKBA) reported Q4 earnings of ($0.05) per share, missing consensus estimates by $0.02, though revenue of $57.62 million exceeded expectations. Despite the EPS miss and continued unprofitability, Vafseo adoption is accelerating, and the company's financial profile strengthened in 2025 with $184.8M in cash providing at least a two-year runway. Akebia plans to expand into rare kidney disease programs with upcoming clinical trials.
